Raphael Gilson
Research Subjects
Research Interests
Raphael Gilson has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Arnaud Bourdin
Department of Respiratory Diseases, Montpellier University Hospital, Arnaud de Villeneuve Hospital, Montpellier, France
5 shared publications - Celia Vidal
Biostatistics Department Montpellier University and Montpellier Teaching Hospital Montpellier France
5 shared publications - Dany Jaffuel
Groupe Adène, Montpellier, France
5 shared publications - Frédéric Gagnadoux
Department of Respiratory and Sleep Medicine, Angers University hospital, Angers, France
5 shared publications - Jean-Pierre Mallet
Groupe Adène, Montpellier, France
5 shared publications - Nicolas Molinari
Biostatistics Department Montpellier University and Montpellier Teaching Hospital Montpellier France
5 shared publications
Latest Publications
- Open Access
- 11 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6424
Positive Airway Pressure-Related Aerophagia in Obstructive Sleep Apnea: Results from the InterfaceVent Real-Life Study
Background: Continuous positive airway pressure (CPAP) effectiveness can be compromised by adverse effects. Despite its potential impact on adherence and sleepiness, aerophagia remains under-recognized and poorly characterized. This ancillary analysis of the InterfaceVent study aimed to identify risk factors for aerophagia in a large real-life cohort of CPAP-treated patients and to assess its association with both CPAP adherence and sleepiness. Methods: InterfaceVent was a prospective, real-life, cross-sectional study. Adults treated for at least 3 months with CPAP were included. Patients self-reported mask-related side effects using visual analogue scales. Aerophagia was defined as a dichotomous outcome based on patient-reported symptoms and CPAP non-adherence as mean nightly usage p < 0.001). CPAP usage was significantly lower in the aerophagia group (median 6.37 vs. 6.75 h/day; p = 0.001), whereas non-adherence, did not significantly differ between groups (10.7% vs. 7.5%; p = 0.20). Conclusions: This ancillary analysis of the InterfaceVent study highlights the burden of aerophagia in CPAP-treated patients and identifies modifiable and non-modifiable risk factors. Better recognition and management of this under-reported side effect may improve CPAP adherence and patient comfort. Trial registration: InterfaceVent is registered with ClinicalTrials.gov (NCT03013283). The first registration date is 23 December 2016.
- 11 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6424
Open AccessPositive Airway Pressure-Related Aerophagia in Obstructive Sleep Apnea: Results from the InterfaceVent Real-Life Study
Background: Continuous positive airway pressure (CPAP) effectiveness can be compromised by adverse effects. Despite its potential impact on adherence and sleepiness, aerophagia remains under-recognized and poorly characterized. This ancillary analysis of the InterfaceVent study aimed to identify risk factors for aerophagia in a large real-life cohort of CPAP-treated patients and to assess its association with both CPAP adherence and sleepiness. Methods: InterfaceVent was a prospective, real-life, cross-sectional study. Adults treated for at least 3 months with CPAP were included. Patients self-reported mask-related side effects using visual analogue scales. Aerophagia was defined as a dichotomous outcome based on patient-reported symptoms and CPAP non-adherence as mean nightly usage p < 0.001). CPAP usage was significantly lower in the aerophagia group (median 6.37 vs. 6.75 h/day; p = 0.001), whereas non-adherence, did not significantly differ between groups (10.7% vs. 7.5%; p = 0.20). Conclusions: This ancillary analysis of the InterfaceVent study highlights the burden of aerophagia in CPAP-treated patients and identifies modifiable and non-modifiable risk factors. Better recognition and management of this under-reported side effect may improve CPAP adherence and patient comfort. Trial registration: InterfaceVent is registered with ClinicalTrials.gov (NCT03013283). The first registration date is 23 December 2016.
- Open Access
- 12 July 2025
- Published by Springer Nature in Respiratory Research
- Vol. 26 (1) , 1-7
Concerns arising from the calculation of the apnea-hypopnea index during CPAP-telemonitoring of patients with obstructive sleep apnea
Continuous Positive Airway Pressure (CPAP) telemonitoring is increasingly important in managing obstructive sleep apnea (OSA). The Apnea-Hypopnea Index reported by CPAP devices (AHIflow) is used as a key indicator of treatment effectiveness. However, discrepancies in AHIflow calculation rules between manufacturers may affect clinical decision-making. No prior studies have investigated whether manufacturers’ choices to exclude certain apnea-hypopnea events from the AHIflow calculation may influence the number of patients presenting an AHIflow alert. The aim of this proof-of-concept study was not to compare the manufacturers with each other, but to evaluate, for each manufacturer, how the different possible ways of calculating AHIflow influence the percentage of alert cases. We conducted a retrospective analysis of 13,764 CPAP-treated OSA patients monitored on October 2, 2023. AHIflow calculations were evaluated according to manufacturer-specific rules. When possible, we assessed the impact of excluding central hypopneas, events during major leaks, and/or ramp periods on the percentage of patients crossing the consensual AHIflow alert threshold of ≥ 10 events/h. We identified significant disparities in AHIflow calculations between manufacturers, which lead to significant differences in the number of patients flagged as being in an alert state. Excluding central hypopneas reduced the number of alert cases by 50%, while excluding apneas/hypopneas during major leaks or ramp periods reduced alerts by 20%. Our proof-of-concept study highlights inconsistencies in AHIflow calculations among CPAP manufacturers, raising concerns about patient care. Establishing standardized AHIflow calculation criteria is essential to ensuring accurate monitoring and optimal patient safety.
- 12 July 2025
- Published by Springer Nature in Respiratory Research
- Vol. 26 (1) , 1-7
Open AccessConcerns arising from the calculation of the apnea-hypopnea index during CPAP-telemonitoring of patients with obstructive sleep apnea
Continuous Positive Airway Pressure (CPAP) telemonitoring is increasingly important in managing obstructive sleep apnea (OSA). The Apnea-Hypopnea Index reported by CPAP devices (AHIflow) is used as a key indicator of treatment effectiveness. However, discrepancies in AHIflow calculation rules between manufacturers may affect clinical decision-making. No prior studies have investigated whether manufacturers’ choices to exclude certain apnea-hypopnea events from the AHIflow calculation may influence the number of patients presenting an AHIflow alert. The aim of this proof-of-concept study was not to compare the manufacturers with each other, but to evaluate, for each manufacturer, how the different possible ways of calculating AHIflow influence the percentage of alert cases. We conducted a retrospective analysis of 13,764 CPAP-treated OSA patients monitored on October 2, 2023. AHIflow calculations were evaluated according to manufacturer-specific rules. When possible, we assessed the impact of excluding central hypopneas, events during major leaks, and/or ramp periods on the percentage of patients crossing the consensual AHIflow alert threshold of ≥ 10 events/h. We identified significant disparities in AHIflow calculations between manufacturers, which lead to significant differences in the number of patients flagged as being in an alert state. Excluding central hypopneas reduced the number of alert cases by 50%, while excluding apneas/hypopneas during major leaks or ramp periods reduced alerts by 20%. Our proof-of-concept study highlights inconsistencies in AHIflow calculations among CPAP manufacturers, raising concerns about patient care. Establishing standardized AHIflow calculation criteria is essential to ensuring accurate monitoring and optimal patient safety.
- 28 February 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (1) , 1-11
Added value of technician intervention to improve mask management for apneic patients treated with long-term CPAP
Purpose Long-term management of sleep apnea patients treated with CPAP raises questions about the cost-effectiveness of certain resources. With the growing use of remote CPAP monitoring and patient questionnaires, the importance of direct patient supervision by technicians is being challenged. To date, no real-life study has investigated the long-term additional value of a technician in evaluating common CPAP side effects compared to patient-reported side effects. Methods InterfaceVent-CPAP is a prospective real-life cross-sectional study conducted in a cohort of apneic adults treated with CPAP for at least 3 months. Three common CPAP side effects (pain, erythema, and leaks) were independently assessed by the patient and the technician on visual analogue scales and diagrams, respectively. CPAP-reported leaks were also collected. Gwet’s concordance coefficient was used to analyze concordance between patient and technician assessments of CPAP side effects. Results 1484 patients (median age 67 years (IQ25–75: 60–74)) were evaluated by 32 technicians. Correlation between CPAP-reported leaks and technician-reported leaks was weak. For pain and erythema, moderate to high concordance was observed between technician and patient responses, while no concordance was found for leaks. Univariate linear regression analyses examining the effect of technician-reported areas of pain, erythema and leaks on the Epworth-Sleepiness-Scale revealed statistically significant associations between sleepiness in women and certain technician-reported areas of mask leaks and mask pain. Conclusion Direct supervision of chronic apneic patients by technicians adds value in managing mask-related issues. Long-term care should include a combination of remote CPAP monitoring, patient-reported outcomes, and technician direct supervision. Trial Registration InterfaceVent is registered with ClinicalTrials.gov (NCT03013283). First registration date is 2016-12-23.
- 28 February 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (1) , 1-11
Added value of technician intervention to improve mask management for apneic patients treated with long-term CPAP
Purpose Long-term management of sleep apnea patients treated with CPAP raises questions about the cost-effectiveness of certain resources. With the growing use of remote CPAP monitoring and patient questionnaires, the importance of direct patient supervision by technicians is being challenged. To date, no real-life study has investigated the long-term additional value of a technician in evaluating common CPAP side effects compared to patient-reported side effects. Methods InterfaceVent-CPAP is a prospective real-life cross-sectional study conducted in a cohort of apneic adults treated with CPAP for at least 3 months. Three common CPAP side effects (pain, erythema, and leaks) were independently assessed by the patient and the technician on visual analogue scales and diagrams, respectively. CPAP-reported leaks were also collected. Gwet’s concordance coefficient was used to analyze concordance between patient and technician assessments of CPAP side effects. Results 1484 patients (median age 67 years (IQ25–75: 60–74)) were evaluated by 32 technicians. Correlation between CPAP-reported leaks and technician-reported leaks was weak. For pain and erythema, moderate to high concordance was observed between technician and patient responses, while no concordance was found for leaks. Univariate linear regression analyses examining the effect of technician-reported areas of pain, erythema and leaks on the Epworth-Sleepiness-Scale revealed statistically significant associations between sleepiness in women and certain technician-reported areas of mask leaks and mask pain. Conclusion Direct supervision of chronic apneic patients by technicians adds value in managing mask-related issues. Long-term care should include a combination of remote CPAP monitoring, patient-reported outcomes, and technician direct supervision. Trial Registration InterfaceVent is registered with ClinicalTrials.gov (NCT03013283). First registration date is 2016-12-23.
- 23 January 2025
- Published by Elsevier in Sleep Medicine
- Vol. 128, 22-28
The influence of atmospheric temperature on long-term CPAP-usage in patients with obstructive sleep apnea
- 23 January 2025
- Published by Elsevier in Sleep Medicine
- Vol. 128, 22-28
The influence of atmospheric temperature on long-term CPAP-usage in patients with obstructive sleep apnea
- Open Access
- 6 September 2024
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-12
Mask side-effects are related to gender in long-term CPAP: results from the InterfaceVent real-life study
Over the past three decades, our understanding of sleep apnea in women has advanced, revealing disparities in pathophysiology, diagnosis, and treatment compared to men. However, no real-life study to date has explored the relationship between mask-related side effects (MRSEs) and gender in the context of long-term CPAP. The InterfaceVent-CPAP study is a prospective real-life cross-sectional study conducted in an apneic adult cohort undergoing at least 3 months of CPAP with unrestricted mask-access (34 different masks, no gender specific mask series). MRSE were assessed by the patient using visual analog scales (VAS). CPAP-non-adherence was defined as a mean CPAP-usage of less than 4 h per day. The primary objective of this ancillary study was to investigate the impact of gender on the prevalence of MRSEs reported by the patient. Secondary analyses assessed the impact of MRSEs on CPAP-usage and CPAP-non-adherence depending on the gender. A total of 1484 patients treated for a median duration of 4.4 years (IQ25–75: 2.0–9.7) were included in the cohort, with women accounting for 27.8%. The prevalence of patient-reported mask injury, defined as a VAS score ≥ 5 (p = 0.021), was higher in women than in men (9.6% versus 5.3%). For nasal pillow masks, the median MRSE VAS score for dry mouth was higher in women (p = 0.039). For oronasal masks, the median MRSE VAS score for runny nose was higher in men (p = 0.039). Multivariable regression analyses revealed that, for both women and men, dry mouth was independently and negatively associated with CPAP-usage, and positively associated with CPAP-non-adherence. In real-life patients treated with long-term CPAP, there are gender differences in patient reported MRSEs. In the context of personalized medicine, these results suggest that the design of future masks should consider these gender differences if masks specifically for women are developed. However, only dry mouth, a side effect not related to mask design, impacts CPAP-usage and non-adherence.
- 6 September 2024
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-12
Open AccessMask side-effects are related to gender in long-term CPAP: results from the InterfaceVent real-life study
Over the past three decades, our understanding of sleep apnea in women has advanced, revealing disparities in pathophysiology, diagnosis, and treatment compared to men. However, no real-life study to date has explored the relationship between mask-related side effects (MRSEs) and gender in the context of long-term CPAP. The InterfaceVent-CPAP study is a prospective real-life cross-sectional study conducted in an apneic adult cohort undergoing at least 3 months of CPAP with unrestricted mask-access (34 different masks, no gender specific mask series). MRSE were assessed by the patient using visual analog scales (VAS). CPAP-non-adherence was defined as a mean CPAP-usage of less than 4 h per day. The primary objective of this ancillary study was to investigate the impact of gender on the prevalence of MRSEs reported by the patient. Secondary analyses assessed the impact of MRSEs on CPAP-usage and CPAP-non-adherence depending on the gender. A total of 1484 patients treated for a median duration of 4.4 years (IQ25–75: 2.0–9.7) were included in the cohort, with women accounting for 27.8%. The prevalence of patient-reported mask injury, defined as a VAS score ≥ 5 (p = 0.021), was higher in women than in men (9.6% versus 5.3%). For nasal pillow masks, the median MRSE VAS score for dry mouth was higher in women (p = 0.039). For oronasal masks, the median MRSE VAS score for runny nose was higher in men (p = 0.039). Multivariable regression analyses revealed that, for both women and men, dry mouth was independently and negatively associated with CPAP-usage, and positively associated with CPAP-non-adherence. In real-life patients treated with long-term CPAP, there are gender differences in patient reported MRSEs. In the context of personalized medicine, these results suggest that the design of future masks should consider these gender differences if masks specifically for women are developed. However, only dry mouth, a side effect not related to mask design, impacts CPAP-usage and non-adherence.